Guardant Health, Inc. (NASDAQ:GH) Receives $39.31 Average Target Price from Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have earned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $39.31.

Several research analysts have recently weighed in on GH shares. Jefferies Financial Group assumed coverage on Guardant Health in a research note on Monday, June 3rd. They issued a “buy” rating and a $32.00 price target for the company. Craig Hallum boosted their target price on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their price target on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 18th. The Goldman Sachs Group boosted their price objective on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Finally, Stephens restated an “overweight” rating and set a $44.00 price objective on shares of Guardant Health in a research report on Friday, May 24th.

Guardant Health Stock Up 0.2 %

Shares of NASDAQ:GH opened at $23.77 on Friday. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. Guardant Health has a 52-week low of $15.81 and a 52-week high of $37.04. The firm has a market capitalization of $2.92 billion, a P/E ratio of -6.06 and a beta of 1.11. The stock has a 50 day moving average price of $29.42 and a 200-day moving average price of $24.70.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The company had revenue of $177.24 million during the quarter, compared to analysts’ expectations of $162.59 million. During the same quarter in the previous year, the company earned ($0.67) EPS. The business’s quarterly revenue was up 29.2% on a year-over-year basis. As a group, equities research analysts anticipate that Guardant Health will post -3.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Several large investors have recently bought and sold shares of GH. Quarry LP purchased a new position in Guardant Health in the second quarter worth about $44,000. Manchester Capital Management LLC bought a new stake in shares of Guardant Health in the 1st quarter valued at approximately $57,000. Canton Hathaway LLC purchased a new position in shares of Guardant Health in the 2nd quarter worth approximately $59,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Guardant Health during the 2nd quarter valued at approximately $71,000. Finally, Van ECK Associates Corp raised its holdings in Guardant Health by 29.4% during the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after buying an additional 614 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.